QV Investors Inc. trimmed its holdings in Solventum Corporation (NYSE:SOLV – Free Report) by 29.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 154,502 shares of the company’s stock after selling 64,190 shares during the quarter. QV Investors Inc.’s holdings in Solventum were worth $13,619,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Solventum in the second quarter worth about $150,066,000. Bank of America Corp DE boosted its position in Solventum by 0.6% during the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock worth $93,561,000 after acquiring an additional 9,083 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Solventum during the second quarter worth about $61,460,000. Dimensional Fund Advisors LP grew its stake in Solventum by 44.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock valued at $50,576,000 after acquiring an additional 236,659 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Solventum by 16,656.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock valued at $42,570,000 after acquiring an additional 480,048 shares in the last quarter.
Solventum Trading Up 1.5%
Shares of SOLV stock opened at $86.35 on Wednesday. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16. The company’s 50-day moving average price is $88.68 and its 200-day moving average price is $80.31. The stock has a market cap of $14.70 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 1.31 and a beta of 0.63.
Solventum (NYSE:SOLV – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same period last year, the business earned $1.69 earnings per share. Solventum’s revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts predict that Solventum Corporation will post 7.22 earnings per share for the current year.
Wall Street Analysts Forecast Growth
SOLV has been the topic of several recent research reports. Mizuho set a $113.00 target price on Solventum in a report on Thursday, August 6th. KeyCorp upped their price target on Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Benchmark reaffirmed a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Wedbush lifted their price objective on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Finally, UBS Group lifted their price objective on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Moderate Buy” and a consensus price target of $92.80.
About Solventum
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.
The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.
Featured Stories
- Five stocks we like better than Solventum
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
